Condition: Systemic Lupus Erythematosus · Antiphospholipid Syndrome · Sponsor: Hospital for Special Surgery, New York
The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic factors predict pregnancy complications in patients with aPL antibodies and/or SLE.
This description comes directly from the study's public registry record.
Marta M. Guerra, MS · 212-774-7361 · guerram@hss.edu
Always discuss trial participation with your own doctor first.
| Northwestern University | Chicago, Illinois, United States | Completed |
| University of Chicago | Chicago, Illinois, United States | Completed |
| Johns Hopkins Hospital | Baltimore, Maryland, United States | Completed |
| NYU Langone Medical Center/Hospital for Joint Diseases | New York, New York, United States | Recruiting |
| Hospital for Special Surgery | New York, New York, United States | Recruiting |
| Columbia University Medical Center | New York, New York, United States | Completed |
| Oklahoma Medical Research Foundation | Oklahoma City, Oklahoma, United States | Completed |
| University of Utah Salt Lake City | Salt Lake City, Utah, United States | Recruiting |
| Mt. Sinai Hospital | Toronto, Ontario, Canada | Recruiting |
| Guy's & St Thomas' NHS Foundation Trust | London, United Kingdom | Completed |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT00198068